Scarica l'app Stockscreener
228.44
0.45%
-1.04
Dopo l'orario di chiusura:
228.78
0.34
+0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$229.48
Aprire:
$229
Volume 24 ore:
4.87M
Relative Volume:
0.76
Capitalizzazione di mercato:
$403.74B
Reddito:
$61.16B
Utile/perdita netta:
$4.19B
Rapporto P/E:
96.74
EPS:
2.3614
Flusso di cassa netto:
$17.82B
1 W Prestazione:
-1.90%
1M Prestazione:
+4.19%
6M Prestazione:
+8.47%
1 anno Prestazione:
+11.94%
Intervallo 1D:
$227.67
$230.76
Intervallo di 1 settimana:
$223.02
$234.00
Portata 52W:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
228.44 | 405.58B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
1,042.15 | 998.60B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.28 | 592.45B | 94.19B | 26.80B | 19.70B | 11.05 |
|
AZN
Astrazeneca Plc
|
206.61 | 317.72B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
167.11 | 314.27B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Tests Exclusion Strategy In Drug Price Fight - Law360
How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative - Yahoo Finance
AbbVie makes $380 million ‘made in the U.S.’ move - thestreet.com
Governor Pritzker Announces Major AbbVie Manufacturing Expansion - RiverBender.com
AbbVie to spend $380M on two new manufacturing facilities in Illinois - Manufacturing Dive
Is AbbVie Stock Underperforming the Dow? - Barchart.com
AbbVie Plans to Launch Offering of Senior Notes - marketscreener.com
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference - Investing News Network
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income - Nasdaq
AbbVie announces $380m investment in North Chicago API facilities - Pharmaceutical Technology
FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL - Yahoo! Finance Canada
North Chicago-based AbbVie investing $380 million on new pharmaceutical plants - Chicago Sun-Times
AbbVie (ABBV) to Invest $380M in New Pharmaceutical Plants - GuruFocus
AbbVie to invest $380 million to expand US manufacturing in Illinois - 1470 & 100.3 WMBD
AbbVie reveals blueprints for two new manufacturing sites in Chicago - FirstWord Pharma
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States - Investing News Network
AbbVie to build 2 more manufacturing facilities in North Chicago with $380M investment - The Business Journals
AbbVie plans to spend $380 million building two new manufacuturing facilities in North Chicago - Yahoo Finance
'Forefront of innovation': State announces major $380M expansion at AbbVie in Lake County, creating 300 new jobs - Lake and McHenry County Scanner
Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential - Finviz
AbbVie plans $380 million manufacturing expansion in North Chicago - StreetInsider
AbbVie to build 2 new manufacturing facilities at North Chicago headquarters, company and Gov. Pritzker announce - WGN-TV
AbbVie plans $380M manufacturing expansion in Illinois - Investing.com
AbbVie (ABBV) Invests $380M in New Manufacturing Facilities - GuruFocus
AbbVie to Invest $380 Million in Chicago to Further Expand US API Manufacturing - CHEManager
AbbVie to Invest $380 Million in 2 New Facilities in Illinois - marketscreener.com
AbbVie to Invest $380 Million to Construct 2 Active Pharmaceutical Ingredient Production Sites in Chicago - marketscreener.com
AbbVie to invest $380M in two API manufacturing facilities at Illinois campus - TipRanks
AbbVie announces $380 million investments in North Chicago - marketscreener.com
Abbvie Announces $380 Million Investments In North Chicago - TradingView
AbbVie investing $380M on two new plants in North Chicago, adding 300 employees - Crain's Chicago Business
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States – Company AnnouncementFT.com - Financial Times
Students - AbbVie
UK's NICE Recommends AbbVie's Follicular Lymphoma Drug - marketscreener.com
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs - The Globe and Mail
Theodora Ross Joins Ideaya, Leaving Impact on AbbVie (ABBV) - GuruFocus
AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142 - The Globe and Mail
Heartland Bank & Trust Co Has $3.85 Million Position in AbbVie Inc. $ABBV - MarketBeat
Siligmueller & Norvid Wealth Advisors LLC Purchases Shares of 12,436 AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Upgraded to Strong-Buy at Barclays - MarketBeat
Fiera Capital Corp Has $38.12 Million Stake in AbbVie Inc. $ABBV - MarketBeat
New Graduates & Entry-Level positions - AbbVie
ABBV Stock Quote Price and Forecast - CNN
Beyond the Balance Sheet: What SWOT Reveals About AbbVie Inc (AB - GuruFocus
Evercore notes AbbVie Inc.’s (ABBV) Tremfya gains market share, but future earnings growth may be limited - MSN
Students & New Graduates - AbbVie
AbbVie Inc. SEC 10-K Report - TradingView
AbbVie wins FDA nod for leukemia therapy (update) (ABBV:NYSE) - Seeking Alpha
Woodley Farra Manion Portfolio Management Inc. Buys 11,527 Shares of AbbVie Inc. $ABBV - MarketBeat
Barclays Initiates Coverage on ABBV with Overweight Rating | ABB - GuruFocus
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):